Loading...
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial
IMPORTANCE: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE: To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN,...
Na minha lista:
| Udgivet i: | JAMA Neurol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Medical Association
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838630/ https://ncbi.nlm.nih.gov/pubmed/29255900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.3859 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|